SML1899
SR144528
≥98% (HPLC), CB2 receptor inverse agonist, powder
别名:
5-(4-Chloro-3-methylphenyl)-1-[(4-methylphenyl)methyl]-N-[(1S,2S,4R)-1,3,3-trimethylbicyclo[2.2.1]hept-2-yl]-1H-pyrazole-3-carboxamide, SR-144528
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C29H34ClN3O
化学文摘社编号:
分子量:
476.05
NACRES:
NA.77
UNSPSC Code:
12352200
MDL number:
产品名称
SR144528, ≥98% (HPLC)
InChI key
SUGVYNSRNKFXQM-XRHWURSXSA-N
SMILES string
C[C@]12[C@H](NC(C3=NN(CC4=CC=C(C)C=C4)C(C5=CC=C(Cl)C(C)=C5)=C3)=O)C(C)(C)[C@@H](C2)CC1
InChI
1S/C29H34ClN3O/c1-18-6-8-20(9-7-18)17-33-25(21-10-11-23(30)19(2)14-21)15-24(32-33)26(34)31-27-28(3,4)22-12-13-29(27,5)16-22/h6-11,14-15,22,27H,12-13,16-17H2,1-5H3,(H,31,34)/t22-,27-,29+/m1/s1
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 10 mg/mL, clear
storage temp.
−20°C
Quality Level
Application
SR144528 has been used as a cannabinoid CB2 receptor antagonist:
- to study its blocking effect on the anti-dyskinetic functionality of HU-308
- to study its effects on spontaneous excitatory postsynaptic currents (sEPSCs) from the globus pallidus neurons
- to analyze its effect on the gastric emptying in rats
Biochem/physiol Actions
SR144528 is a potent and highly selective cannabinoid CB2 receptor inverse agonist.
SR144528 is a potent and highly selective cannabinoid CB2 receptor inverse agonist. SR144528 exhibited a Ki of 0.6 nM at CB2 compared to 400 nM at the related CB1 receptor.
存储类别
11 - Combustible Solids
wgk
WGK 3
I Freiman et al.
Neuroscience, 133(1), 305-313 (2005-05-17)
The globus pallidus receives its major glutamatergic input from the subthalamic nucleus and subthalamic nucleus neurons synthesize CB1 cannabinoid receptors. The hypothesis of the present work was that CB1 receptors are localized in terminals of subthalamo-pallidal glutamatergic axons and that
M Rinaldi-Carmona et al.
The Journal of pharmacology and experimental therapeutics, 284(2), 644-650 (1998-03-07)
Based on both binding and functional data, this study introduces SR 144528 as the first, highly potent, selective and orally active antagonist for the CB2 receptor. This compound which displays subnanomolar affinity (Ki = 0.6 nM) for both the rat
Qiang Tan et al.
Brain research, 1654(Pt A), 24-33 (2016-10-23)
Fibrosis in ventricular system has a role in hydrocephalus following intraventricular hemorrhage (IVH). The cannabinoid receptor 2 (CB2) has been reported to participate in alleviating the fibrosis process of many diseases. However, its role in fibrosis after IVH was unclear
A A Izzo et al.
Naunyn-Schmiedeberg's archives of pharmacology, 360(2), 221-223 (1999-09-24)
We have studied the effect of WIN 55,212-2 (a psychoactive cannabinoid agonist), cannabinol (a nonpsychoactive cannabinoid agonist), SR141716A, a cannabinoid CB1 antagonist, and SR144528, a cannabinoid CB2 antagonist, on gastric emptying in the rat. WIN 55,212-2 (0.1-5 mg/kg, i.p.) and
Peggy Rentsch et al.
Neurobiology of disease, 134, 104646-104646 (2019-11-02)
L-dopa induced dyskinesia (LID) is a debilitating side-effect of the primary treatment used in Parkinson's disease (PD), l-dopa. Here we investigate the effect of HU-308, a cannabinoid CB2 receptor agonist, on LIDs. Utilizing a mouse model of PD and LIDs
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持